A Science and Technology Blog
In all, 492 severe and serious AEFI have been classified by the AEFI Secretariat of the immunisation technical support unit (ITSU) at the Health Ministry. Classification has been completed for…
Names of the ten members Dr. Varsha Gupta, Professor, Department of Microbiology, Government Medical College Hospital, Chandigarh; 2) Dr. Archana Thakur, Medical Director, Professor and HOD (Microbiology), G.B. Pant Hospital,…
The Subject Expert Committee (SEC) has permitted Bharat Biotech to unblind all phase-3 trial participants above 45 years and offer the vaccine to those who received a placebo. The reason: vaccines (including Covaxin) are already available under the immunisation programme, and therefore all the eligible age groups should be unblinded for vaccination.
By following the U.K. model of vaccinating people based on age bands rather than focussing on comorbidities, millions of people would become eligible to receive the vaccine and be fully…
According to details posted on the clinical trial registry, the company had planned to “continue the phase-3 trial until 130 study participants developed PCR-confirmed symptomatic COVID-19 disease during follow-up beginning…
While it is unclear if pre-existing antibodies to adenovirus vector will affect vaccine efficacy, it is possible that repeated vaccination using adenovirus-based vaccine either as a booster or as annual vaccination, if the need arises, will result in reduced efficacy due to vector immunity.
The vaccine efficacy was measured based on symptomatic COVID-19 disease — mild, moderate or severe — two weeks after the second dose. The interim analysis undertaken at the first endpoint…
“The list of comorbidities provided by the Health Ministry is overly restrictive and complicated. Many conditions, including obesity, have been left out,” says Dr. Gagandeep Kang, Professor of Microbiology at…
